Condition

Chondrosarcoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting1

Common interventions12

Lead sponsors shown5

Clinical trials

5 shown

PET-imaging of Two Vartumabs in Patients With Solid TumorsNCT06645808 · 2024-12-10

RECRUITING

The Registry of Oncology Outcomes Associated With Testing and TreatmentNCT04028479 · 2021-05-05

COMPLETED

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686 · 2020-10-01

ACTIVE_NOT_RECRUITING

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastNCT04091295

AVAILABLE

Tazemetostat Expanded Access Program for Adults With Solid TumorsNCT03874455

NO_LONGER_AVAILABLE

Common interventions

89Zr-DFO-N-Suc-C9scFvBIOLOGICAL1 89Zr-DFO-N-Suc-F8scFvBIOLOGICAL1 Biomarker Testing (L)DIAGNOSTIC_TEST1 CisplatinDRUG1 DNG64-CAR-VDRUG1 DurvalumabDRUG1 GemcitabineDRUG1 LY3410738DRUG1 Patient Reported Outcomes (P)OTHER1 PET/CT scanRADIATION1 Systemic Treatment (T)DRUG1 TazemetostatDRUG1

Leading sponsors

Aveni Foundation 1 Eli Lilly and Company 1 Epizyme, Inc. 1 Taproot Health 1 Var2 Pharmaceuticals 1

Trial status mix

ACTIVE_NOT_RECRUITING1

AVAILABLE1

COMPLETED1

NO_LONGER_AVAILABLE1

RECRUITING1

Phase mix

EARLY_PHASE11

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.